Not every patient needs every MTC service, and asking about a GLP-1 medication does not guarantee eligibility
Heimbrger SM, Bergmann NC, Augustin R, Gasbjerg LS, Christensen MB, Knop FK
NDA submission estimated Q4 2026-Q1 2027, commercial availability ~2028.Master Guide | Clinical Data | Compare GLP-1s | Dosage Calculator | Blog
If you want to learn more about the benefits people experience with this peptide, take a look at our post on Retatrutide benefits for a detailed breakdown
Jeffrey Egler, Nooms Chief Medical Officer, puts it, lower dose does not mean lower responsibility. In fact, because microdosing requires slower, more deliberate titration, it often demands more oversight than the standard protocol